Keywords: Eli Lilly, Tabalumab, Rheumatoid arthritis, Ph III, Discontinued

Eli Lilly drops one tabalumab trial for RA

Article | 14 December 2012

Print This

US drug major Eli Lilly (NYSE: LLY) says that it will stop one of three Phase III rheumatoid arthritis (RA) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in